The role of gap junction intercellular communication (GJIC) in ischemia-induced focal ventricular tachycardia (VT) is unknown. We have developed a new, stable antiarrhythmic peptide analog named ZP123 that selectively increases GJIC and prevents reentrant VT. Our aim in this study was to use ZP123 as a tool to assess the role of GJIC on occurrence of ischemia-induced focal VT and triggered activity (TA) due to delayed afterdepolarizations (DADs). Focal VT was induced by programmed stimulation in ␣-chloralose-anesthetized, open-chest dogs 1-4 h after coronary artery occlusion. Three-dimensional activation mapping was done using 6 bipolar electrograms on each of 23 multipolar needles in the risk zone. Dogs were randomly assigned to receive either saline or ZP123 cumulatively at three dose levels (an intravenous bolus followed by a 30-min infusion per dose). Attempts to induce VT were repeated in each dose. Mass spectrometry was used to measure plasma ZP123 concentrations. Standard microelectrode techniques were used for in vitro study of DADs and TA. Twenty-six dogs with focal VT were included. ZP123 did not affect the inducibility of focal VT at any plasma concentrations vs. saline (0.8 Ϯ 0.1 nM, 77 vs. 75%; 7.8 Ϯ 0.4 nM, 86 vs. 77%; and 78.8 Ϯ 5.0 nM, 77 vs. 91%). In vitro, ZP123 did not affect the induction of DADs (12/12) and TAs (10/10) in ischemic tissues or tissue removed from the origin of focal VT (DADs, 8/8; TAs, 4/4). Therefore, although indirect, the data with the doses and concentrations used suggest that GJIC may not play a major role in the genesis of focal activity in the ischemic models studied.
gap junction intercellular communication; myocardial; delayed afterdepolarizations ISCHEMIA-RELATED ventricular tachycardia (VT) may be caused by either a reentrant or focal mechanism. Whereas there is good evidence to support a role for decreased gap junction intercellular communication (GJIC) in the formation of slowconduction and unidirectional block leading to reentry (11) , little experimental data are available on the role of GJIC in the formation of focal VT. Computer simulations have suggested (6, 18) that reduced GJIC such as during ischemia may promote the formation of ectopic foci by decreasing the electrotonic load on the cells. However, the same simulation studies demonstrated that reduced GJIC may prevent the impulse from propagating and thereby suppress VT (6, 16) . Thus the role of GJIC on the initiation and propagation of focal activity is still unclear.
We have developed a highly stable, antiarrhythmic peptide analog called ZP123 (Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH 2 ) that increases GJIC (17) , prevents conduction slowing during acidosis (5) , and reduces action potential (AP) dispersion (5, 8) . Previously, we demonstrated that ZP123 prevents the induction of epicardial reentry VT during coronary artery occlusion by preventing unidirectional conduction block (17) . In the present experiments, we used ZP123 as a tool to test the opposing hypothesis predicted from the simulation studies, that increased GJIC would 1) either prevent or promote the induction of focal VT during myocardial ischemia in intact dogs, and 2) suppress or facilitate induction of delayed afterdepolarizations (DADs) and triggered activities (TAs) in vitro in endocardial sites removed from ischemic areas.
METHODS
Twenty-six adult mongrel dogs of either sex (10 -20 kg body wt) were used for the study. The Animal Care and Use Review Board at the University of Iowa approved the protocol, which conformed with the guidelines of the American Physiological Society.
Surgical preparation. Dogs were pretreated with injections of 0.05 ml/kg im acepromazine maleate (10 mg/ml) mixed with 0.1 ml/kg im ketamine hydrochloride (100 mg/ml). Anesthesia was induced by administration of 0.4 ml/kg iv thiopental sodium (25 mg/ml) followed by an ␣-chloralose (150 mg/kg) bolus. Anesthesia was maintained by constant infusion of ␣-chloralose (8 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 dissolved in saline and polyethylene glycol, mol wt 200). The dogs were intubated and mechanically ventilated on a volume-cycled respirator (Harvard) to maintain a PO 2 of 80 -110 mmHg, a PCO2 of 35-45 mmHg, and a pH of 7.35-7.45 (Radiometer; Copenhagen, Denmark). The femoral vein and artery were cannulated for administration of fluid and drugs and for continuous measurement of mean arterial blood pressure (MAP), respectively.
The pericardium was incised through a midline sternotomy and sutured to the wound edges to form a pericardial support for the heart. A silk suture was passed under the left anterior descending (LAD) coronary artery 1 cm from the left atrial appendage. The suture was threaded in tubing to form a snare for coronary artery occlusion. As opposed to our previous study on the role of GJIC in reentry VT (17) , no visible collateral vessels were ligated in this study. Epicardial temperature was maintained at ϳ37°C by an infrared heating lamp and a plastic sheet draped over the sternotomy. Warm saline was applied to the heart intermittently to prevent surface drying.
Electrophysiological preparation. Surface ECG leads were recorded continuously. The sinus node was permanently clamped. The atria were stimulated at twice diastolic threshold with pulses of 2-ms duration with a bipolar electrode at a cycle length (CL) of 300 ms. To record transmural signals, 23 16-pole plunge-needle electrodes (J. Kassell; Fayetteville, NC) were inserted into the myocardium in and surrounding the risk zone of the LAD artery as previously reported (1) (2) (3) . The interneedle distance was ϳ1 cm depending on individual coronary artery anatomy.
Bipolar electrograms were recorded from Յ6 different sites on each 16-pole electrode (1) . To maximize the capability of recording from Purkinje fibers, noise-free bipolar signals were chosen by sequential recording on a storage oscilloscope of each successive bipole. Purkinje, endocardial, midwall, and epicardial electrograms were chosen as previously described (3) . Electrograms were recorded simultaneously on two computers, and three-dimensional (3-D) activation maps were developed (1, 2) .
Experimental protocol. Blood gas values and adequate anesthesia levels were confirmed before LAD artery occlusion. The effective refractory period (ERP) was determined, and VT was induced by programmed electrical stimulation using up to four premature stimuli (S2-S5; Refs. 1, 2, 17). Pacing protocols were started 1 h after occlusion. Previous studies (2, 17) using this model have demonstrated that VT may be reproducibly induced over this period. Sustained VTs were usually terminated by pacing or were cardioverted with epicardial shocks of 10 -20 J. Repeat testing was done from apical, septal, or lateral left ventricular pacing sites every 20 min and was continued until the successful induction of two episodes of VT with similar surface-lead morphology. If VTs with similar morphology could not be induced twice within 3 h after occlusion, the experiment was terminated. In dogs in which VT was reproducibly induced, ZP123 or saline was given randomly and cumulatively as a bolus (11 ϫ 10 Ϫ7 , 11 ϫ 10 Ϫ6 , or 11 ϫ 10 Ϫ5 g/kg iv) followed by a 30-min infusion (2.1 ϫ 10 Ϫ9 , 2.1 ϫ 10 Ϫ8 , and 2.1 ϫ 10 Ϫ7 g ⅐ min Ϫ1 ⅐ kg Ϫ1 iv, respectively) (17) . At 20 min into each infusion, extrastimulus testing was performed from the same pacing site(s), which induced VT during the control period. A blood sample was taken at the end of each infusion period for later determination of plasma ZP123 concentration.
Intracellular recording techniques. After 3-D activation mapping was performed, one focal origin of VT was located, and the heart was excised and placed in Tyrode solution with the following composition (in mM): 125 NaCl, 24 NaHCO3, 4.5 KCl, 1.8 CaCl2, 0.5 MgCl2, 0.25 NaHPO4, and 5.5 dextrose (pH 7.4). Endocardial focal tissue blocks (4 ϫ 3 ϫ 2 mm) were removed from the area of the mapping electrode that recorded the focus and were pinned in a 3-ml tissue bath (Warner Instruments). The tissue was superfused with Tyrode solution (37°C) at a rate of 9 ml/min. Fibers were stimulated with a bipolar electrode at twice diastolic threshold. AP measurements were performed during pacing at 1.5-5 Hz. The most superficial cells were impaled with 3 M KCl-filled glass capillary microelectrodes with tip resistances of 3-20 M⍀. Microelectrodes were connected to a high-input impedance preamplifier (Axoclamp-2A; Axon Instruments; Foster City, CA). The bath was grounded with an Ag-AgCl pellet. Potentials were recorded and stored on a computer with the use of commercial software (Axon Instruments) with data filtered at 1 kHz and sampled at 2 kHz. Zero offsets were recorded to correct for drift. Purkinje cells were identified by spontaneous phase 4 depolarization or automaticity at CL Ͼ 1 s. If there were no DADs or TAs inducible, isoproterenol (0.5 M) was added. Tissues were first assessed for the presence or absence of DADs and TAs before and during isoproterenol superfusion. ZP123 was then added to the superfusate at 1, 10, and 100 nM concentrations to determine the effects of the drug on DADs and TAs. Washout of the drug and isoproterenol was also performed.
Definitions and analysis. Mapping of electrograms was done offline as previously described (1, 2, 17) . VT was defined as at least five consecutive nonstimulated ventricular complexes, and sustained VT was defined as VT that did not self-terminate within 10 s; most episodes of VT were pace terminated. Ventricular fibrillation (VF) was defined as an irregular ventricular rhythm that resulted in hemodynamic collapse and required a shock to terminate. The CL of each VT episode was measured by averaging the first (up to 10) CLs. VT mechanisms were defined as follows: reentrant VT occurred when the electrode recording the earliest activity was immediately adjacent to the site of the latest activation from the previous complex, and diastolic activity was recorded between complexes. Focal VT occurred when the electrode recording the site of origin (SOO) was surrounded on six sides by other electrodes within 1-2 cm that recorded progressive and gradually later activity while moving away from the SOO. There was no late (Ͼ50% cycle) electrical activity on adjacent sites. Ischemia was defined by voltage reduction as in our prior report (1) .
Depolarizations occurring after phase 3 of paced APs were defined as DADs. Nonpaced APs occurring at the peak of a DAD showing overdrive stimulation were defined as TAs.
ZP123 assay. The plasma concentration of ZP123 was measured by a combined liquid chromatography and mass spectrometry analysis of samples after solid-phase extraction as previously described (8) .
Statistical analysis. The effect of ZP123 on the incidence of VT, DADs, and TAs was analyzed by a two-tailed Fisher's exact test at each dose level. The effects of ZP123 on VT CL, ERP, and MAP were analyzed by a two-way ANOVA with repeated measurements. P Ͻ 0.05 was considered statistically significant. All values are means Ϯ SE.
RESULTS
In vivo experiments during myocardial ischemia. Twentysix dogs with focal VT were randomized to ZP123 (n ϭ 14) or saline (n ϭ 12) groups. Figure 1 shows induction of focal VT in one experiment. Several sites recorded the earliest activity before the surface QRS, but site E-F persisted as the SOO for the subsequent VT. Note that all surrounding activity in 3-D space suggests focal activation with no late activation that would be expected with reentrant excitation. Figure 2 shows the 3-D map with endocardial and Purkinje foci separated by later activation times especially in propagation to the epicardium. These figures demonstrate the typical focal VT originating from the endocardium that was evaluated in this study.
Focal VT was reinduced from the same pacing site with similar protocols (Table 1 ) in both groups. The saline and ZP123 groups had reproducible VTs (at least twice after dosing) in all but one and two experiments, respectively. Compared with saline, ZP123 did not significantly reduce the incidence of focal VT at any dose ( Table 2 ). The number of foci recorded at the origin of each VT averaged three per experimental period (as illustrated by the representative example in Fig. 1 ) and was not changed by ZP123. The overall incidence of acceleration to VF in VT episodes after treatment was similar in the two groups (ZP123, 7 of 14 dogs; saline, 6 of 12 dogs; not significant), especially because each of these also had VF before drug treatment except for experiments in the saline-treated group. Thus ZP123 neither prevented nor promoted the induction of focal VT.
The mean CLs of the VTs were similar in the two groups before treatment and averaged 131 Ϯ 3 ms in the ZP123 group and 134 Ϯ 3 ms in the saline group (see Table 1 ). Neither group had any change in CL after treatment (see Table 1 ). MAP and ERP values were also unaffected by ZP123 treatment (MAP: control, 96 Ϯ 4; highest ZP123 dose, 91 Ϯ 4 mmHg; ERP: control, 153 Ϯ 3; highest ZP123 dose, 152 Ϯ 3 ms). Similarly, the size of the ischemic area was stable over time and unaltered by ZP123 (control, 68 Ϯ 4; highest ZP123 dose, 68 Ϯ 3% of risk zone). Consistent with the prior study (17) , electrogram duration in the epicardium of the last premature stimulus shortened from 29 Ϯ 3 to 26 Ϯ 3 ms.
In vitro experiments in previously ischemic endocardium. ZP123 did not affect AP characteristics (Table 3) , which is consistent with the lack of effect on membrane currents reported previously (5, 17) . Also, ZP123 did not prevent the induction of DADs (10 of 12 dogs) and TAs (8 of 10 dogs) in ischemic tissues; in two preparations, DADs and repetitive TAs appeared to be reversibly blocked. Moreover, in those tissues, which did not have TAs, ZP123 did not Fig. 2 . Three-dimensional ventricular activation maps of the second VT complex of Fig. 1 . Each rectangle represents a plane of activation times (given at each electrode site) in milliseconds (from onset of the surface QRS in Fig. 1 ) in the left ventricular epicardium (Epi), subepicardium (S-Epi), midwall, subendocardium (S-Endo), endocardium (Endo), and Purkinje (Purk) layers. On each rectangle, the left vertical (west) lies along the left anterior descending artery and north horizontal runs along the coronary sinus. South horizontal is at the apex. First site (P-F in Fig. 1; yellow) is activated in Purkinje tissue at Ϫ16 ms before the QRS and a simultaneous early site (E-F in Fig. 1 at Ϫ16 ) occurs in endocardium. Other colors (red, green, and blue) represent subsequent 20-ms isochrones. Overall transmural activation is from endocardium to epicardium with the latest sites activated in the epicardial layers by the left anterior descending artery. Note that the two focal sites of origin are separated by a later activation in endocardium (E-C in Fig. 1 ) at Ϫ6 ms. All surrounding activity activated sequentially without late activity thereby eliminating reentry as a mechanism. All subsequent maps of this VT show a similar activation pattern with one focus at E-F (see Fig. 1 ).
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GJIC STIMULATION DOES NOT AFFECT FOCAL ACTIVITY facilitate the induction nor was abnormal automaticity exposed. Normal automaticity was uncovered in five preparations not observed before ZP123 was superfused, and the CLs ranged from 4.4 to 9 s; however, no early afterdepolarizations (EADs) were observed at these CLs. In eight experiments, we were able to remove tissue from the SOO of focal VT and record APs and responses to stimuli and isoproterenol. We saw no inhibition of induction of DADs (8 of 8 dogs), or TAs (4 of 4 dogs; Fig. 3 ). In addition, we also saw no facilitation of TAs in the four tissues with DADs alone.
ZP123 plasma concentrations. The incremental plasma concentrations of ZP123 at the end of each infusion period were 0.8 Ϯ 0.1, 7.8 Ϯ 0.4, and 78.8 Ϯ 5.0 nM, respectively.
DISCUSSION
A number of studies have investigated the influence of cell-to-cell coupling on the initiation and propagation of focal activity by using simulated cardiac tissue or model cells coupled to isolated ventricular cardiomyocytes (6, 12, 14 -16) . However, the lack of compounds that selectively affect gap junctions has hindered in vivo testing of the predictions generated from computer simulations. The development of ZP123, a new, stable, antiarrhythmic peptide analog that specifically increases GJIC without affecting ion channels (8, 17) , enables testing of the influence of GJIC on focal activity in cell systems, whole hearts, and in vivo. We previously evaluated (8) the effects of ZP123 in a murine model of ouabain-induced VF; however, to our knowledge, the present study is the first to investigate the influence of GJIC in a large-animal in vivo model of known focal arrhythmia.
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propagation is dependent on the degree of anisotropy with the chance of propagation being higher in anisotropic tissue, because the impulse is focused in a certain direction, which allows neighboring cells to reach threshold (16) . According to this, conditions such as ischemia and infarction that may increase the anisotropic ratio would facilitate focal arrhythmias. Eloff et al. (5) recently showed that the anisotropic ratio is increased during acidosis in isolated, perfused guinea pig hearts due to a more severe slowing of conduction velocity in the transverse than the longitudinal direction. They also showed that 80 nM ZP123 was able to prevent the conduction velocity slowing and the increased anisotropy during acidosis, which suggests that ZP123 may prevent facilitation of impulse propagation by limiting anisotropy (5) . However, the present study showed that ZP123 neither facilitated nor suppressed focal activity. There was no effect of ZP123 on the inducibility of focal VT or the number of ectopic foci during VT in dogs 1-4 h after LAD artery occlusion. However, although our conclusions are perhaps applicable to a clinical pathophysiological substrate, they do not exclude other models with different doses and concentrations that produce greater effects on GJIC from showing an effect. Previously, we investigated the effects of ZP123 and another synthetic antiarrhythmic peptide analog, AAP10, on the time to VF during ouabain infusion (8) . In this model, VF is likely caused by the formation of DADs and TAs associated with the high intracellular Ca 2ϩ levels that result from ouabain infusion. ZP123 and AAP10 failed to dose dependently prevent VF, although both compounds significantly delayed the time until second-degree atrioventricular block, which is an indirect measure of prevention of Ca 2ϩ -induced uncoupling of gap junction channels. Thus the lack of effect of ZP123 on ouabain-induced VF in the murine study suggested a lack of effect of increased GJIC on DADs and focal VT. By looking directly at focal VT with 3-D mapping, we have in the present study confirmed this suggested lack of effect. Thus contrary to what may be predicted from computer simulation studies, ZP123 neither suppressed automaticity nor facilitated propagation. Previously we showed that ZP123 at the same doses as used in the present study prevented reentrant VT at all doses in the ischemic dog model of programmed electrical stimulation-induced VT (17) . Therefore, the lack of effect of ZP123 on focal VT cannot be ascribed to the use of ineffective doses of the compound. Consistent with our finding that ZP123 does not promote focal arrhythmias during ischemia, we did not see an increase in focal activity after reentrant VT was blocked in our previous study (17) .
In the present study, we also investigated the effects of ZP123 on DADs and TAs in vitro in tissues removed from ischemic endocardial sites, some of which were at the SOO of a focal VT in vivo. We found that these events were neither facilitated nor clearly blocked by ZP123, which thus explains the lack of effect of ZP123 on ouabain-induced VF that was previously seen (8) . Only very slow Purkinje automaticity occurring at normal resting membrane potentials appeared with ZP123 superfusion.
Several studies have shown that when normal, isolated ventricular cardiomyocytes or Purkinje cells are coupled to a passive resistance circuit to simulate ischemic cells with depolarized resting membrane potentials, EADs form in the real cell (6, 14) . When the coupling conductance is increased, the EADs disappear. In cells in which EADs were induced by norepinephrine, the EADs could be suppressed by coupling the cell to a simulated cell with nearly normal resting membrane potential; however, when the cell was coupled to a partly depolarized simulated cell, the cell generated multiple EADs instead of a single EAD (14) . From these simulations, it seems that the effect of coupling is highly related to the state of the coupled cells. In the present study, although the tissue was obtained from ischemic endocardial sites, the resting membrane potentials were nearly normal during measurements, and EADs were not observed. The reason that these cells were able to withstand the prolonged ischemia may be related to their location in close proximity to the cavity, where they received some oxygen and nutrients from the cavity blood. Also, the tissue was allowed to equilibrate in Tyrode solution for at least 30 min before recordings were obtained. Fig. 3 . Effects of ZP123 on delayed afterdepolarizations (DADs) and triggered activities (TAs). Pace induction (upward arrows) of DADs (downward arrows) and TAs (between upward and downward arrows) during superfusion with isoproterenol (Iso; 0.5 M) before and after the addition of ZP123. ZP123 had no effect on the induction of DADs and TAs. Note the phase 4 depolarization defining Purkinje tissue. Values are means SE; n ϭ 7 dogs per ZP123 dosage group. APD50, APD70, and APD90, action potential durations at 50, 70, and 90% repolarization, respectively.
As expected from previous studies with ZP123 and other antiarrhythmic peptides (4, 5, 7-10) and in line with its selective effect on GJIC, there was no effect of ZP123 on any of the AP parameters measured during the in vitro study, and there was no effect on ERP or MAP in vivo. However, we cannot exclude that changing parameters of measurement such as the interval of electrodes could show significantly different effects on GJIC.
In summary, the present study showed that ZP123 did not affect automaticity or propagation of focal activity either in vivo in dogs 1-4 h after LAD artery occlusion or in vitro in tissue from ischemic endocardium. New gap junction-modifying compounds like ZP123, which show promising potential for the prevention of reentrant VT, may not prevent focal VT. Whether this difference was due to improved conduction caused by increased GJIC is speculative as it is based in indirect observations with limited apparent effect produced. Because the relative importance of focal and reentrant mechanisms in ischemia-induced life-threatening ventricular tachyarrhythmias is unknown, clinical trials with ZP123 may provide important information to address this fundamental question.
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